Cargando…

Hemoglobin A1c Reduction With the GLP-1 Receptor Agonist Semaglutide Is Independent of Baseline eGFR: post hoc Analysis of the SUSTAIN and PIONEER Programs

INTRODUCTION: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are effective treatments for reducing hemoglobin A1c (HbA1c) in people with type 2 diabetes (T2D), including those with reduced kidney function. METHODS: This post hoc analysis assessed the HbA1c-lowering efficacy of semaglutide, a G...

Descripción completa

Detalles Bibliográficos
Autores principales: Cherney, David Z.I., Hadjadj, Samy, Lawson, Jack, Mosenzon, Ofri, Tuttle, Katherine, Vrhnjak, Blaz, Rasmussen, Søren, Bain, Stephen C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9751689/
https://www.ncbi.nlm.nih.gov/pubmed/36531884
http://dx.doi.org/10.1016/j.ekir.2022.07.167
_version_ 1784850533126766592
author Cherney, David Z.I.
Hadjadj, Samy
Lawson, Jack
Mosenzon, Ofri
Tuttle, Katherine
Vrhnjak, Blaz
Rasmussen, Søren
Bain, Stephen C.
author_facet Cherney, David Z.I.
Hadjadj, Samy
Lawson, Jack
Mosenzon, Ofri
Tuttle, Katherine
Vrhnjak, Blaz
Rasmussen, Søren
Bain, Stephen C.
author_sort Cherney, David Z.I.
collection PubMed
description INTRODUCTION: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are effective treatments for reducing hemoglobin A1c (HbA1c) in people with type 2 diabetes (T2D), including those with reduced kidney function. METHODS: This post hoc analysis assessed the HbA1c-lowering efficacy of semaglutide, a GLP-1RA, in participants with a range of kidney functions in the SUSTAIN 4–6 and 10 (subcutaneous semaglutide) and PIONEER 5 and 6 (oral semaglutide) clinical trials. Trial-level changes from baseline to end of treatment (EOT) in HbA1c and body weight (BW) were assessed in participants with estimated glomerular filtration rate (eGFR) >15 ml/min per 1.73 m(2) by subgroups categorized according to baseline eGFR. Adverse events were also evaluated. RESULTS: The analysis included 8859 participants. The mean comparator-adjusted reduction in HbA1c from baseline to EOT with semaglutide ranged from 0.6% to 1.6% points across trials, with similar reductions across the eGFR subgroups (interaction P-value ≥ 0.33 for difference between eGFR subgroups within each trial). Greater weight loss from baseline to EOT with semaglutide versus comparator was observed across almost all baseline eGFR subgroups, with nominally greater weight loss with lower versus higher eGFR in SUSTAIN 6 and 10 and PIONEER 5 and 6 (interaction P < 0.05). No new safety concerns with semaglutide were identified. CONCLUSION: The HbA1c-lowering effect of semaglutide in participants with T2D was comparable irrespective of eGFR, which ranged upwards from eGFR >15 ml/min per 1.73 m(2).
format Online
Article
Text
id pubmed-9751689
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-97516892022-12-16 Hemoglobin A1c Reduction With the GLP-1 Receptor Agonist Semaglutide Is Independent of Baseline eGFR: post hoc Analysis of the SUSTAIN and PIONEER Programs Cherney, David Z.I. Hadjadj, Samy Lawson, Jack Mosenzon, Ofri Tuttle, Katherine Vrhnjak, Blaz Rasmussen, Søren Bain, Stephen C. Kidney Int Rep Clinical Research INTRODUCTION: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are effective treatments for reducing hemoglobin A1c (HbA1c) in people with type 2 diabetes (T2D), including those with reduced kidney function. METHODS: This post hoc analysis assessed the HbA1c-lowering efficacy of semaglutide, a GLP-1RA, in participants with a range of kidney functions in the SUSTAIN 4–6 and 10 (subcutaneous semaglutide) and PIONEER 5 and 6 (oral semaglutide) clinical trials. Trial-level changes from baseline to end of treatment (EOT) in HbA1c and body weight (BW) were assessed in participants with estimated glomerular filtration rate (eGFR) >15 ml/min per 1.73 m(2) by subgroups categorized according to baseline eGFR. Adverse events were also evaluated. RESULTS: The analysis included 8859 participants. The mean comparator-adjusted reduction in HbA1c from baseline to EOT with semaglutide ranged from 0.6% to 1.6% points across trials, with similar reductions across the eGFR subgroups (interaction P-value ≥ 0.33 for difference between eGFR subgroups within each trial). Greater weight loss from baseline to EOT with semaglutide versus comparator was observed across almost all baseline eGFR subgroups, with nominally greater weight loss with lower versus higher eGFR in SUSTAIN 6 and 10 and PIONEER 5 and 6 (interaction P < 0.05). No new safety concerns with semaglutide were identified. CONCLUSION: The HbA1c-lowering effect of semaglutide in participants with T2D was comparable irrespective of eGFR, which ranged upwards from eGFR >15 ml/min per 1.73 m(2). Elsevier 2022-08-03 /pmc/articles/PMC9751689/ /pubmed/36531884 http://dx.doi.org/10.1016/j.ekir.2022.07.167 Text en © 2022 Published by Elsevier, Inc., on behalf of the International Society of Nephrology. https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Clinical Research
Cherney, David Z.I.
Hadjadj, Samy
Lawson, Jack
Mosenzon, Ofri
Tuttle, Katherine
Vrhnjak, Blaz
Rasmussen, Søren
Bain, Stephen C.
Hemoglobin A1c Reduction With the GLP-1 Receptor Agonist Semaglutide Is Independent of Baseline eGFR: post hoc Analysis of the SUSTAIN and PIONEER Programs
title Hemoglobin A1c Reduction With the GLP-1 Receptor Agonist Semaglutide Is Independent of Baseline eGFR: post hoc Analysis of the SUSTAIN and PIONEER Programs
title_full Hemoglobin A1c Reduction With the GLP-1 Receptor Agonist Semaglutide Is Independent of Baseline eGFR: post hoc Analysis of the SUSTAIN and PIONEER Programs
title_fullStr Hemoglobin A1c Reduction With the GLP-1 Receptor Agonist Semaglutide Is Independent of Baseline eGFR: post hoc Analysis of the SUSTAIN and PIONEER Programs
title_full_unstemmed Hemoglobin A1c Reduction With the GLP-1 Receptor Agonist Semaglutide Is Independent of Baseline eGFR: post hoc Analysis of the SUSTAIN and PIONEER Programs
title_short Hemoglobin A1c Reduction With the GLP-1 Receptor Agonist Semaglutide Is Independent of Baseline eGFR: post hoc Analysis of the SUSTAIN and PIONEER Programs
title_sort hemoglobin a1c reduction with the glp-1 receptor agonist semaglutide is independent of baseline egfr: post hoc analysis of the sustain and pioneer programs
topic Clinical Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9751689/
https://www.ncbi.nlm.nih.gov/pubmed/36531884
http://dx.doi.org/10.1016/j.ekir.2022.07.167
work_keys_str_mv AT cherneydavidzi hemoglobina1creductionwiththeglp1receptoragonistsemaglutideisindependentofbaselineegfrposthocanalysisofthesustainandpioneerprograms
AT hadjadjsamy hemoglobina1creductionwiththeglp1receptoragonistsemaglutideisindependentofbaselineegfrposthocanalysisofthesustainandpioneerprograms
AT lawsonjack hemoglobina1creductionwiththeglp1receptoragonistsemaglutideisindependentofbaselineegfrposthocanalysisofthesustainandpioneerprograms
AT mosenzonofri hemoglobina1creductionwiththeglp1receptoragonistsemaglutideisindependentofbaselineegfrposthocanalysisofthesustainandpioneerprograms
AT tuttlekatherine hemoglobina1creductionwiththeglp1receptoragonistsemaglutideisindependentofbaselineegfrposthocanalysisofthesustainandpioneerprograms
AT vrhnjakblaz hemoglobina1creductionwiththeglp1receptoragonistsemaglutideisindependentofbaselineegfrposthocanalysisofthesustainandpioneerprograms
AT rasmussensøren hemoglobina1creductionwiththeglp1receptoragonistsemaglutideisindependentofbaselineegfrposthocanalysisofthesustainandpioneerprograms
AT bainstephenc hemoglobina1creductionwiththeglp1receptoragonistsemaglutideisindependentofbaselineegfrposthocanalysisofthesustainandpioneerprograms